MedPage Today

Topical Agent for Hyperhidrosis Wins FDA Approval

The FDA approved sofpironium topical gel 12.45% (Sofdra) for primary axillary hyperhidrosis, according to a statement from Botanix Pharmaceuticals. The approval stipulates use in adults and children 9 ...
Healio

How to treat ‘disabling’ hyperhidrosis in children and adults

Hyperhidrosis is undertreated and underappreciated as a condition that causes distress for patients, yet available treatment ...
Healio

FDA approves Sofdra gel for primary axillary hyperhidrosis

Please provide your email address to receive an email when new articles are posted on . Sofdra (sofpironium) gel 12.45% is the first and only chemical entity for primary axillary hyperhidrosis. The ...
Medscape

FDA Approves New Treatment for Primary Axillary Hyperhidrosis

The Food and Drug Administration has approved a topical anticholinergic, sofpironium topical gel, 12.45%, for the treatment of primary axillary hyperhidrosis in adults and children aged ≥ 9 years.
Business Insider

Dermira’s QBREXZA™ (glycopyrronium) Cloth Is Now Available in Pharmacies Nationwide for the Treatment of Primary Axillary Hyperhidrosis

QBREXZA is the first and only FDA-approved, once-daily, topical prescription treatment indicated for people 9 years of age and older with primary axillary hyperhidrosis, also known as excessive ...
Monthly Prescribing Reference

Sofdra Approved for Primary Axillary Hyperhidrosis

Sofpironium bromide indirectly reduces the rate of sweating by preventing the stimulation of acetylcholine receptors that are located on sweat glands. The Food and Drug Administration (FDA) has ...
clinicaladvisor.com

Sofpironium Bromide Improves Primary Hyperhidrosis Severity, Sweat Reduction

Sofpironium bromide in the treatment of primary axillary hyperhidrosis improves Hyperhidrosis Disease Severity Scale scores, reduces gravimetric weight of sweat, and improves Dermatology Life Quality ...
National Institute for Health and Care Excellence

Transcutaneous microwave ablation for severe primary axillary hyperhidrosis

Current evidence on the safety and efficacy of transcutaneous microwave ablation for severe primary axillary hyperhidrosis is inadequate in quantity and quality. Therefore, this procedure should only ...
Nasdaq

Dermata Receives Notice of Grant of Australian Patent for Topical Botulinum Toxin Treatment for Hyperhidrosis

- This is the Company's second granted patent for DMT410, using its Spongilla technology to topically deliver botulinum toxin for hyperhidrosis - - The Company recently entered into a Clinical Trial ...
Nasdaq

Dermata and Revance Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari(TM) with Daxxify(R)

SAN DIEGO, CA and SOUTH SAN FRANCISCO, CA / ACCESS Newswire / January 21, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata") and Revance ...
Business Insider

Dermira Presents New Data Highlighting Patient Outcomes in Axillary Hyperhidrosis at Maui Derm MeetingProprietary Axillary Sweating Daily Diary patient-reported outcome ...

MENLO PARK, Calif., March 21, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering ...